BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ilias A, Szanto K, Gonczi L, Kurti Z, Golovics PA, Farkas K, Schafer E, Szepes Z, Szalay B, Vincze A, Szamosi T, Molnar T, Lakatos PL. Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade. Clinical Gastroenterology and Hepatology 2019;17:2506-2513.e2. [DOI: 10.1016/j.cgh.2018.12.036] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Abraham B, Eksteen B, Nedd K, Kale H, Patel D, Stephens J, Shelbaya A, Chambers R, Soonasra A. Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study). Adv Ther 2022. [PMID: 35296993 DOI: 10.1007/s12325-022-02104-6] [Reference Citation Analysis]
2 Mak JW, Sung JJ. The Use of Biologics and Biosimilar in Asian patients with IBD: Are we ready? J Gastroenterol Hepatol 2019;34:1269-70. [PMID: 31456235 DOI: 10.1111/jgh.14817] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
3 Buchner AM, Schneider Y, Lichtenstein GR. Biosimilars in Inflammatory Bowel Disease. Am J Gastroenterol 2021;116:45-56. [DOI: 10.14309/ajg.0000000000000844] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Mantaka A, Orfanoudaki E, Koutroubakis IE. Letter to the Editor: Is There a Role for Switching Infliximab in Order to Regain Anti-TNF Response in Cases With Active Inflammatory Bowel Disease? Inflamm Bowel Dis 2019;25:e120. [PMID: 31300823 DOI: 10.1093/ibd/izz153] [Reference Citation Analysis]
5 Schreiber S, Puig L, Gonçalves J, Mease PJ, Panaccione R, Emery P. Critical Appraisal and Future Outlook on Anti-Inflammatory Biosimilar Use in Chronic Immune-Mediated Inflammatory Diseases. Seminars in Arthritis and Rheumatism 2022. [DOI: 10.1016/j.semarthrit.2022.152023] [Reference Citation Analysis]
6 Luber RP, O'Neill R, Singh S, Sharma E, Cunningham G, Honap S, Meade S, Ray S, Anderson SH, Mawdsley J, Sanderson JD, Samaan MA, Arkir Z, Irving PM. An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch. Aliment Pharmacol Ther 2021;54:678-88. [PMID: 34223654 DOI: 10.1111/apt.16497] [Reference Citation Analysis]
7 Patil SA, Bhat S, Limdi JK, Farraye FA, Cross RK. The Sincerest Form of Flattery? Biosimilars in Inflammatory Bowel Disease. Inflamm Bowel Dis 2022:izac048. [PMID: 35353189 DOI: 10.1093/ibd/izac048] [Reference Citation Analysis]
8 Ho SL, Niu F, Pola S, Velayos FS, Ning X, Hui RL. Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study. BioDrugs 2020;34:395-404. [PMID: 32103457 DOI: 10.1007/s40259-020-00409-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
9 Goncalves J, Myung G, Park M, Jeong D, Ghil J. SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis. Therap Adv Gastroenterol 2019;12:1756284819891081. [PMID: 31839806 DOI: 10.1177/1756284819891081] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
10 Mahmmod S, Schultheiss JPD, van Bodegraven AA, Dijkstra G, Gilissen LPL, Hoentjen F, Lutgens MWMD, Mahmmod N, van der Meulen-de Jong AE, Smits LJT, Tan ACITL, Oldenburg B, Fidder HH. Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izaa364. [PMID: 33538298 DOI: 10.1093/ibd/izaa364] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
11 Solitano V, D'Amico F, Fiorino G, Peyrin-Biroulet L, Danese S. Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice. Expert Rev Clin Immunol 2020;16:1019-28. [PMID: 32954893 DOI: 10.1080/1744666X.2021.1826311] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
12 Feagan BG, Marabani M, Wu JJ, Faccin F, Spronk C, Castañeda-Hernández G. The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence. Adv Ther 2020;37:4491-518. [PMID: 32910420 DOI: 10.1007/s12325-020-01472-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
13 D'Amico F, Solitano V, Peyrin-Biroulet L, Danese S. Nocebo effect and biosimilars in inflammatory bowel diseases: what's new and what's next? Expert Opin Biol Ther 2021;21:47-55. [PMID: 32857634 DOI: 10.1080/14712598.2020.1817374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]